ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,050.61
-0.39%
Dow Jones
43,449.90
-0.61%
US Dollar vs MXN
20.2032
0.13%
Brent Oil
73.035
-0.10%
Bitcoin
103,685.83
-2.32%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Exagen Inc (XGN) Cotización

Exagen Inc

Exagen Inc (XGN)

NASDAQ
5.80
-0.20
(-3.33%)
Cerrado 17 Diciembre 3:00PM
Delayed by 15 minutes
5.80
0.00
(0.00%)
Fuera de horario: 6:59PM
Delayed by 15 minutes

Herramientas de nivel profesional para inversores individuales.

Premium

Estadísticas y detalles clave

Último Precio
5.80
Postura de Compra
5.70
Postura de Venta
6.08
Volume Operado de la Acción
196,313
5.60 Rango del Día 6.12
1.3003 Rango de 52 semanas 6.21
Capitalización de Mercado [m]
102.296M
Precio Anterior
6.00
Precio de Apertura
6.02
Hora
1
@
5.87
Última hora de negociación
Volumen financiero
US$ 1,146,677
Precio Promedio Ponderado
5.8411
Volumen promedio (3 m)
72,296
Acciones en circulación
17,637,278
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-4.34
Beneficio por acción (BPA)
-1.34
turnover
52.55M
Beneficio neto
-23.69M

Acerca de Exagen Inc

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differentia... Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists. Mostrar más

Sector
Medical Laboratories
Industria
Medical Laboratories
Sitio web
www.exagen.com
Sede
Wilmington, Delaware, USA
Fundado
-
Exagen Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker XGN. The last closing price for Exagen was US$6. Over the last year, Exagen shares have traded in a share price range of US$ 1.3003 to US$ 6.21.

Exagen currently has 17,637,278 shares in issue. The market capitalisation of Exagen is US$105.82 million. Exagen has a price to earnings ratio (PE ratio) of -4.34.

XGN Últimas noticias

Más noticias

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

12 Diciembre 2024
Edgar (US Regulatory)

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the completion of its 1,000,000th AVISE CTD test, marking a significant...

12 Diciembre 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

27 Noviembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

19 Noviembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

18 Noviembre 2024
Edgar (US Regulatory)

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic...

14 Noviembre 2024
GlobeNewswire Inc.

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the...

13 Noviembre 2024
GlobeNewswire Inc.

Exagen Inc. Reports Third Quarter 2024 Results

Expanded AVISE® CTD trailing twelve-month average selling priceReduced Adjusted EBITDA loss for first three quarters of 2024Revenue in line with expectations, excluding one-time adjustments...

12 Noviembre 2024
GlobeNewswire Inc.

Exagen to Announce Third Quarter 2024 Results on November 12, 2024

CARLSBAD, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended September 30, 2024...

29 Octubre 2024
GlobeNewswire Inc.

Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence

CARLSBAD, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American...

21 Octubre 2024
GlobeNewswire Inc.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
11.368630.88414496554.43146.214.233236555.57077948CS
42.8294.63087248322.986.212.981802404.85659232CS
122.6986.49517684893.116.212.38722964.4559862CS
263.83194.4162436551.976.211.71618763.67432916CS
524.25274.1935483871.556.211.3003549862.88211051CS
156-4.07-41.23606889569.8711.691.3003438903.76212941CS
260-13.08-69.279661016918.8829.8581.3003466329.14562008CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
NUKKNukkleus Inc
US$ 11.655
(738.49%)
174.4M
PRTGPortage Biotech Inc
US$ 8.8678
(172.86%)
36.61M
OPTXSyntec Optics Holdings Inc
US$ 3.55
(99.44%)
93.16M
PTPIPetros Pharmaceuticals Inc
US$ 0.4976
(86.37%)
63.49M
LUXHLuxUrban Hotels Inc
US$ 0.849899
(59.67%)
29.52M
VCNXVaccinex Inc
US$ 1.41
(-61.37%)
758.95k
TNYATenaya Therapeutics Inc
US$ 1.395
(-51.56%)
42.45M
ORKTOrangeKloud Technology Inc
US$ 2.14
(-41.85%)
2.29M
RVPHReviva Pharmaceuticals Holdings Inc
US$ 1.395
(-39.35%)
18.16M
DBGIDigital Brands Group Inc
US$ 2.46
(-37.88%)
805.23k
RIMEAlgorhythm Holdings Inc
US$ 0.0877
(8.27%)
1.13B
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.335
(-36.79%)
1B
GOEVCanoo Inc
US$ 0.118
(7.08%)
382.65M
NVDANVIDIA Corporation
US$ 130.39
(-1.22%)
251.71M
XTIAXTI Aerospace Inc
US$ 0.0442
(8.33%)
221.41M

Discusión

Ver feed completo
4u2nv2 4u2nv2 4 minutos hace
Did VISTAinnova Strategy buy the 4.5 million in MCIC this week? It's a thought.
MCIC
The Whale The Whale 4 minutos hace
Should get the news today.

$ICTY
ICTY
MasterBlastr MasterBlastr 5 minutos hace
Fortunately we have fickle minute-mental voters to make 2026 look better already. Just a matter of stalling and litigating, and hope we can live until we can run another election to correct this last one.
Huggy Bear Huggy Bear 6 minutos hace
I remember perfectly well, and it was all SCAMMING.

And this latest circus show is more of the same, scamming.
HMBL
NoMoDo NoMoDo 7 minutos hace
No...goofy... it really happened. You might not remember, but it really happened.
HMBL
jjjjjjjj jjjjjjjj 8 minutos hace
I have 42M shares in my individual account and 7M shares in the rest I acquired at $0.15. I lost a lot of money. Don't invest if you couldn't lost it all.
MJNA
hondaboost hondaboost 8 minutos hace
NUKK 0.2935 0.3008 0.2601 0.2734 -0.0306 1,228,680 69,714 0.2765 0.3055
2024-10-22 Q NUKK 0.2602 0.3699 0.251 0.304 0.0414 2,896,335 33,108 0.2576 0.304
2024-10-21 Q NUKK 0.2662 0.27 0.2351 0.2626 -0.0036 1,446,129 65,182 0.2377 0.266
2024-10-18 Q NUKK 0.2589 0.2776 0.2401 0.266
NUKK
agua77 agua77 8 minutos hace
I see nothing within the press release which states the intellectual property/patent…I also made that statement in one of my previous posts. I actually think the term “patent” was used by a poster and it stuck in our minds. It sounds more like a R&D company that wants to build out systems. This does
ZHUD
Huggy Bear Huggy Bear 8 minutos hace
Ahh scamming.... Good, right?
HMBL
mr_sano mr_sano 9 minutos hace
Only a moron would applaud getting split in half.
QSEP
excel excel 9 minutos hace
Yep, exactly.
Practice reps.
Mental prep.

I wonder if Cousins got hurt he kept it to himself either for money? ego?
I don't know but he is way off.
dstock07734 dstock07734 10 minutos hace
You know why I put you on ignore list. Your stupidity is profound. You got lucky this time since I saw your post and replied.

Do you know when Merck started the construction? It was in October 2020. By that time, did Merck have any verifiable data about the efficacy on whatever you ta
NWBO
govprs govprs 12 minutos hace
See page 21 https://www.otcmarkets.com/otcapi/company/financial-report/417444/content
GDVM
agua77 agua77 12 minutos hace
Of course we don’t know that…we only hear promises about “numbers”. That’s how these hopium otc tickers work and on top of it you have a CEO trying to insight emotion as opposed to showing the math.

What’s the worse approach to trading and investing? Emotion
ZHUD
zerosnoop zerosnoop 13 minutos hace
game changer aot
QSEP
Horseb4CarT Horseb4CarT 14 minutos hace
You've probably heard this many times too, but this time is different!
NWBO
zerosnoop zerosnoop 14 minutos hace
proven aot
QSEP
zerosnoop zerosnoop 14 minutos hace
And who are the uneducated fools with a low IQ who incorrectly predicted a 500 million share cap increase ? The same fools who don't understand what "debt financing" is, hah hah. It has nothing to do with dilution.

We are seeking to finalize debt financing to ensure a smooth operation
QSEP
zerosnoop zerosnoop 14 minutos hace
We have come a long way together, and we are entering 2025 with a renewed sense of purpose and momentum. The progress made this year sets the stage for a transformative future for QS Energy. Thank you for your commitment, trust, and partnership. Together, we are shaping the future of oil transport e
QSEP
zerosnoop zerosnoop 14 minutos hace
None of this progress would have been possible without the continued support and patience of our shareholders. Your belief in QS Energy’s mission has been instrumental in our ability to navigate challenges and achieve milestones. As we move forward, we invite you to continue supporting our journey t
QSEP
zerosnoop zerosnoop 14 minutos hace
With these foundational achievements in place, we are now poised for a breakthrough year in 2025. Our focus will be on executing our first customer contracts and launching AOT commercially. We are seeking to finalize debt financing to ensure a smooth operational rollout, and we are confident this wi
QSEP
zerosnoop zerosnoop 15 minutos hace
4. Strengthened Financial Framework: Significant efforts have been made to align our funding strategy with our growth objectives. By focusing on responsible financing, we are working to avoid toxic funding sources, preserving value for our shareholders.
QSEP
zerosnoop zerosnoop 15 minutos hace
3. Path to Commercialization: We took the first steps toward the commercial launch of AOT, with plans to formally enter the market in 2025. This includes securing customer contracts and identifying debt financing to support our operational goals.
QSEP
zerosnoop zerosnoop 16 minutos hace
2. Strategic Partnerships Solidified: Through our collaboration with VIPS Petroleum, we forged strategic agreements with state-owned and private energy companies in Southeast Asia, underscoring the demand for innovative, efficiency-enhancing technology in the region.
QSEP
hondaboost hondaboost 16 minutos hace
Computers trading, it always happens like this: pump to high and dump to low. The machine is irrational!
NUKK

Su Consulta Reciente

NASDAQ
XGN
Exagen
NASDAQ
MDIAV
Mediaco
NASDAQ
RELIW
Reliance Global
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados